Bayer Aktiengesellschaft (FRA:BAYN)
33.37
-0.32 (-0.96%)
At close: Dec 5, 2025
Bayer Aktiengesellschaft Employees
Bayer Aktiengesellschaft had 91,864 employees as of December 31, 2024. The number of employees decreased by 5,067 or -5.23% compared to the previous year.
Employees
91,864
Change (1Y)
-5,067
Growth (1Y)
-5.23%
Revenue / Employee
€518,248
Profits / Employee
€2,237
Market Cap
32.72B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 91,864 | -5,067 | -5.23% |
| Dec 31, 2023 | 96,931 | -991 | -1.01% |
| Dec 31, 2022 | 97,922 | 1,972 | 2.06% |
| Dec 31, 2021 | 95,950 | -5 | -0.01% |
| Dec 31, 2020 | 95,955 | -2,782 | -2.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| SAP SE | 109,121 |
| Siemens Aktiengesellschaft | 318,000 |
| Allianz SE | 156,626 |
| Deutsche Telekom AG | 198,194 |
| Siemens Energy AG | 103,000 |
| Rheinmetall AG | 28,539 |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Bayer Aktiengesellschaft News
- 1 day ago - EQS-News: Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis - Wallstreet:Online
- 2 days ago - EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 2 days ago - Evotec & Bayer Launch Phase 2 Trial for Alport Syndrome Treatment - Wallstreet:Online
- 2 days ago - EQS-News: Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome - Wallstreet:Online
- 2 days ago - Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome - Business Wire
- 3 days ago - RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints - Wallstreet:Online
- 3 days ago - RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints - Business Wire
- 3 days ago - Bayer (BAYRY) Achieves Milestone with Pediatric MRI Contrast Agent Study - GuruFocus